EGFR and lung adenocarcinoma: Interestingly, in advanced lung adenocarcinoma patients with EGFR mutations and asymptomatic BM, brain radiotherapy in combination with tyrosine kinase inhibitors (TKIs) could result in better iPFS and OS(iPFS, 21.5 vs. 14.8 months, P = 0.026; mOS, 36 vs. 23 months, P = 0.041) than TKI alone [18].However, another multi-institutional retrospective analysis found no significant differences between treatment with CNS-penetrant tyrosine kinase inhibitors (TKIs) alone versus TKI + CNS-RT in terms of time to progression, iPFS or time to treatment failure [19].